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Abstract
Background  and  objective:  The  aim  of  this  study  was  to  determine  the  efﬁcacy  of  the  cell
salvage system  in  total  hip  arthroplasty  surgeries  and  whether  the  cell  salvage  system  can
reduce the  allogeneic  blood  transfusion  requirement  in  total  hip  arthroplasty  patients.
Methods: We  reviewed  retrospectively  the  medical  records  of  patients  who  underwent  hip
arthroplasty  surgeries  between  2010  and  2012  in  a  university  hospital.  A  total  of  181  arthroplasty
patients  were  enrolled  in  our  study.
Results:  In  the  cell  salvage  group,  the  mean  perioperative  rate  of  allogeneic  blood  transfusion
was signiﬁcantly  lower  (92.53  ±  111.88  mL)  than  that  in  the  control  group  (170.14  ±  116.79  mL;
p <  0.001).  When  the  mean  postoperative  transfusion  rates  were  compared,  the  cell  salvage
group had  lower  values  (125.37  ±  193.33  mL)  than  the  control  group  (152.22  ±  208.37  mL),
although  the  difference  was  not  statistically  signiﬁcant.  The  number  of  patients  receiving  allo-
geneic blood  transfusion  in  the  CS  group  (n  =  29;  43.2%)  was  also  signiﬁcantly  lower  than  control
group (n  =  56;  73.6%;  p  <  0.05).  In  the  logistic  regression  analysis,  perioperative  amount  of  trans-
fusion, odds  ratio  (OR)  −4.257  (95%  CI  −0.502  to  0.184)  and  operation  time,  OR:  2.720  (95%  CI
0.001--0.004)  were  independent  risk  factors  for  the  usage  of  cell  salvage  system.
Conclusion:  Cell  salvage  is  an  effective  strategy  for  reducing  the  need  for  allogeneic  blood
transfusion in  the  perioperative  setting;  it  provides  support  to  patient  blood  management  inter-
ventions. Thus,  we  recommend  the  cell  salvage  system  for  use  in  total  hip  arthroplasty  surgeries
to reduce  the  need  for  allogeneic  blood  transfusion,  if  possible.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.∗ Corresponding author.
E-mail: mbuget@yahoo.com (M.I. Buget).
ttp://dx.doi.org/10.1016/j.bjane.2014.09.009
104-0014/© 2015 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
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autólogo
Dois  anos  de  experiência  com  recuperac¸ão  intraoperatória  de  sangue  em  artroplastia
total  do  quadril
Resumo
Justiﬁcativa  e  objetivo:  O  objetivo  deste  estudo  foi  determinar  a  eﬁcácia  do  sistema  de  res-
gate celular  em  artroplastia  total  de  quadril  e  se  o  sistema  de  recuperac¸ão  intraoperatória  de
sangue pode  reduzir  a  necessidade  de  transfusão  de  sangue  alogênico  em  pacientes  submetidos
à artroplastia  total  de  quadril.
Métodos:  Análise  retrospectiva  dos  prontuários  de  pacientes  submetidos  a  cirurgias  de
artroplastia  de  quadril  entre  2010  e  2012  em  um  hospital  universitário.  No  total,  181  pacientes
submetidos  à  artroplastia  foram  inscritos  no  estudo.
Resultados:  A  média  da  taxa  de  transfusão  de  sangue  alogênico  no  período  perioper-
atório foi  signiﬁcativamente  inferior  no  grupo  de  recuperac¸ão  intraoperatória  de  sangue
(92,53 ±  111,88  mL)  que  no  grupo  controle  (170,14  ±  116,79  mL;  p  <  0,001).  Quando  as  médias
das taxas  de  transfusão  no  pós-operatório  foram  comparadas,  o  grupo  de  recuperac¸ão  intra-
operatória  de  sangue  apresentou  valores  inferiores  (125,37  ±  193,33  mL)  aos  do  grupo  cont-
role (152,22  ±  208,37  mL),  embora  a  diferenc¸a  não  tenha  sido  estatisticamente  signiﬁcativa.  O
número de  pacientes  que  recebeu  transfusão  de  sangue  alogênico  no  grupo  RC  (n  =  29;  43,2%)
também foi  signiﬁcativamente  inferior  ao  do  grupo  controle  (n  =  56;  73,6%;  p  <  0,05).  Na  análise
de regressão  logística,  a  quantidade  de  transfusão  no  período  perioperatório,  a  razão  de  chance
(OR) --4,257  (95%  CI  --0,502--0,184)  e  o  tempo  cirúrgico,  OR:  2,720  (IC  95%  0,001-0,004)  foram
fatores de  risco  independentes  para  o  uso  de  sistema  de  resgate  celular.
Conclusão:  A  recuperac¸ão  intraoperatória  de  sangue  é  uma  estratégia  eﬁcaz  para  reduzir  a
necessidade  de  transfusão  de  sangue  alogênico  no  período  perioperatório,  que  auxilia  no  manejo
sanguíneo  durante  as  intervenc¸ões.  Portanto,  recomendamos  o  sistema  de  recuperac¸ão  intra-
operatória de  sangue  para  uso  em  artroplastia  total  de  quadril  para  diminuir  a  necessidade  de
transfusão  de  sangue  alogênico,  quando  possível.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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indicated  hematological  problems  that  met  our  exclusionIntroduction
Considerable  blood  loss  is  a  frequent  problem  in  patients
undergoing  major  orthopedic  surgery.  Particularly  for
arthroplasty  surgeries,  allogeneic  red  cell  transfusion  is
often  necessary.1 However,  the  probability  of  transi-
tion  of  a  wide  variety  of  viral  diseases  such  as  those
caused  by  hepatitis  B  and  C,  human  immunodeﬁciency
virus,  transmission-transmitted  virus,  West  Nile  virus,
Cytomegalovirus,  Epstein--Barr  virus,  as  well  as  variant
Creutzfeldt--Jakob  disease,  bacterial  contamination,  and
sepsis  are  a  concern  for  allogeneic  blood  transfusion
(ABT).2,3 The  incidence  of  transfusion-transmitted  diseases
decreased  to  very  low  levels  in  many  countries  with  the
modern  laboratory  techniques  (nucleic  acid  testing)  dur-
ing  the  past  years,  but  ABT  still  has  considerable  risks  such
as  cardiac  overload,  transfusion-related  acute  lung  injury,
and  transfusion-related  immunomodulation.  Medical  staff
welded  incorrect  blood  transfusion,  ABO-Rh  mismatch,  and
allergic  reactions  also  as  serious  causes  of  morbidity  and
mortality.4 Although  the  risks  for  transfusion-transmitted
diseases  decreased  to  a  very  low  level  in  the  developed
countries,  many  developing  countries  where  transfusion  ser-
vices  are  insufﬁcient  still  experience  a  high  prevalence  of
such  infections.5 Meanwhile,  for  the  developed  countries,
the  major  concern  for  ABT  is  the  ﬁnancial  cost  of  providing
and  preserving  a  safe  blood  product  rather  than  transfusion-
related  infectious  diseases.5
c
a
pConsequently,  to  reduce  the  need  for  ABT,  different
ethods  are  established,  including  preoperative  autolo-
ous  blood  donation,  normovolemic  hemodilution,  iron  or
rythropoietin  based  patient  blood  management,  and  cell
alvage  (CS)  systems.1,6,7 CS  is  the  process  of  collecting  and
einfusing  autologous  blood.8 Its  main  target  is  to  reduce
nd,  if  possible,  eliminate  the  need  for  ABT  and  diminish
robable  infectious  and  noninfectious  complications.9
The  aim  of  this  study  was  to  examine  the  records  of
atients  who  had  the  CS  system  used  in  their  total  hip
rthroplasty  (THA)  surgery  and  compare  them  with  patients
perated  without  the  CS  system.  In  addition,  we  investi-
ated  if  the  CS  method  can  decrease  the  need  for  ABTs.
ethods
his  study  was  conducted  with  the  approval  of  the  local
thical  Committee  under  approval  no.  2013/14,  dated
7/12/2012.  We  searched  the  database  of  the  medical  fac-
lty  and  retrospectively  evaluated  patients  operated  in  the
epartment  of  Orthopedics  and  Traumatology.  A  total  of  181
HA  patients  were  enrolled  in  our  study.  Of  the  patients,  38
ere  excluded  from  the  study  because  their  medical  recordsriteria.  We  included  67  patients  in  a  CS  (cell  salvage)  group
nd  76  patients  for  control  groups  who  underwent  hip  arthro-
lasty.
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mFigure  1  Flo
We  reviewed  retrospectively  the  medical  records  of
he  patients  who  had  hip  arthroplasty  operation  between
010  and  2012.  We  excluded  study  patients  with  records
f  a  known  history  of  hematological  diseases,  bleeding
onditions,  or  thromboembolic  events.  Low  platelet  count
plt  =  100.000)  and  any  escalation  in  international  nor-
alized  ratio  (INR  >  1.2)  were  also  deﬁned  as  exclusion
riteria.  In  our  institution,  we  use  CS  system  (Medtronic
utolog,  Medtronic  inc.  Minneapolis,  USA)  when  signiﬁcant
lood  loss  is  estimated  or  preoperative  anemia  is  present
Hgb  <  10  g/dL).  We  divided  our  patients  into  2  groups.  One
roup  consisted  of  patients  for  whom  the  CS  system  was  used
uring  the  perioperative  setting.  CS  system  was  not  used
efore  the  surgery  for  any  patient  in  any  group.  The  con-
rol  group  consisted  of  patients  in  whom  the  CS  system  was
ot  used  their  operation.  The  transfusion  threshold  is  8  g/dL
or  healthy  adults  in  our  institution  and  between  8  g/dL  and
0  g/dL  for  patients  with  severe  cardiac  disease,  and  severe
o-morbidities.
Demographic  data,  preoperative  hemoglobin  level,
ematocrit  and  leukocyte  values,  amount  of  blood  for
utologous  transfusion  during  and  after  the  surgery  were
ecorded.  Hemoglobin  level,  hematocrit  values,  leukocyte
alues  at  discharge,  highest  body  temperature  during  the
ostoperative  period,  and  C-reactive  protein  (CRP)  levels
ere  noted  for  both  groups.  ABTs  were  also  recorded  for
he  2  groups.
tatistical analysis
tatistical  analysis  was  performed  using  a  computer  pro-
ram  NCSS  (Number  Cruncher  Statistical  System)  2007&PASS
Power  Analysis  and  Sample  Size)  2008  Statistical  Software
NCSS  LLC,  Kaysville,  Utah,  US).  Descriptive  statistical  meth-
ds  were  used  (mean,  median,  ratio  and  standard  deviation)
(
g
n
brt  of  patients.
o  evaluate  the  study  data.  Independent  samples  test  was
sed  to  compare  normally  distributed  variables  between
roups.  Mann  Whitney  U  test  was  used  for  ordinal  variables
nd  chi-square  test  was  used  for  nominal  data.  For  multivari-
te  evaluations,  enter  logistic  regression  analysis  was  used.
 p-value  <  0.05  was  considered  as  statistically  signiﬁcant.
esults
here  were  67  patients  in  the  CS  group  and  76  patients  in  the
ontrol  group  (Fig.  1).  In  the  CS  group,  41  patients  (61.1%)
eceived  ABT,  and  69  patients  (90.7%)  in  the  control  group
ad  ABT  (preoperative,  postoperative,  or  both).
In  terms  of  sex,  type  of  anesthesia,  and  age,  we  did
ot  detect  any  signiﬁcant  difference  between  the  groups
Table  1).  Female  patients  accounted  for  46  patients  (68.7%)
n  the  CS  group  and  56  (73.7%)  in  the  control  group.  The  per-
entages  of  neuroaxial  and  general  anesthesia  used  in  the  CS
roup  (52.3%  and  47.7%,  respectively)  were  close  to  those
sed  in  the  control  group  (51.3%  and  48.7%,  respectively).
he  mean  age  was  55.82  ±  13.20  years  in  the  CS  group  and
7.82  ±  13.43  years  in  the  control  group.  Operation  time  sig-
iﬁcantly  differed  between  the  groups;  that  is,  surgery  time
as  longer  in  the  CS  group  (152.72  ±  55.08  min)  than  in  the
ontrol  group  (130.13  ±  40.71  min)  (p  <  0.05).
In  the  CS  group,  the  mean  amounts  of  perioper-
tive  allogeneic  blood  transfused  were  signiﬁcantly
ower  (92.53  ±  111.88  mL)  than  that  in  the  control  group
170.14  ±  116.79  mL;  p  <  0.001).  When  comparing  the
ean  postoperative  transfusion  rates,  the  CS  group125.37  ±  193.33  mL)  had  lower  values  than  the  control
roup  (155.22  ±  208.37  mL),  although  the  difference  was
ot  signiﬁcant.  The  number  of  patients  receiving  allogeneic
lood  transfusion  in  the  CS  group  (n  =  29;  43.2%)  was
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Table  1  Patients’  demographic  data.
Cell  salvage  group
(n =  67)
Control  group
(n =  76)
p-value
Sexa
Male  21  (31.3%)  20  (26.3%) >0.05
Female 46  (68.7%)  56  (73.7%)
Type of  anesthesiaa
Neuroaxial  35(52.3%)  39  (51.3%) >0.05
General 32  (47.7%)  37  (48.7%)
Age (mean  ±  SD)  yearsb 55.82  ±  13.20 57.82  ±  13.43 >0.05
Operation  time  (mean  ±  SD)  minb 152.72  ±  55.08 130.13  ±  40.71 0.016c
NS, no signiﬁcant.
a Chi square test.
b
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c p-value <0.05 statistically signiﬁcant.
also  signiﬁcantly  lower  than  control  group  (n  =  56;  73.6%;
p  <  0.05)  (Table  2).
During  the  operation  of  the  patients  in  the  CS  group,  the
mean  amount  of  blood  transfused  from  the  CS  system  was
333.61  ±  170.99  mL.  The  mean  preoperative  hemoglobin  and
hematocrit  values  did  not  differ  signiﬁcantly  from  the  values
at  discharge  in  both  groups  (Table  3).
The  mean  CRP  level,  postoperative  body  temperature,
and  preoperative  leukocyte  levels  did  not  show  any  sig-
niﬁcant  difference.  The  postoperative  leukocyte  level  was
a  little  higher,  though  not  signiﬁcantly,  in  the  CS  group
(Table  4).
We  evaluated  the  effects  of  variables  for  the  usage  of
autologous  blood  transfusion  with  enters  logistic  regression
analysis.  Variables  evaluated  were  operation  time,  preop-
erative  hemoglobin  and  hematocrit  levels,  perioperative
transfusion  and  postoperative  transfusion  amounts.  Periop-
erative  transfusion  and  operation  time  (>140  min)  variables
were  identiﬁed  as  signiﬁcant  (p  <  0.05).  Odds  ratio  for  peri-
operative  transfusion  was  −4.257  (95%  CI  −0.502  to  −0.184)
which  means  that,  4.257  times  less  likely  ABT  was  needed
during  the  operation  in  the  CS  group.  OR  for  operation  time
was  as  2.720  (95%  CI  0.001--0.004);  which  means  that  we
used  CS  system  in  operations  longer  than  140  min;  2.574
times  more  likely.  Per-op  blood  transfusion  and  operation
time  effects  were  independent  risk  factors  for  Cell  Salvage
group  (Table  5).
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Table  2  Blood  transfusion  data.
C
Perioperative  transfusion;  n(%)a 2
Postoperative  transfusion;  n(%)a 2
Perioperative  transfusion  (mL);  mean  ±  SDb 9
Postoperative  transfusion  (mL);  mean  ±SDb 12
Perioperative  cell  salvage  transfusion  (mL);  mean  ±  SD  33
NS, no signiﬁcant.
a Chi square test.
b Mann--Whitney U test.
c p-value <0.05 statistically signiﬁcant.iscussion
n  major  orthopedic  surgeries  such  as  total  hip  arthroplasty
urgeries,  intraoperative  blood  loss  and  associated  anemia
re  frequent.  In  particular,  anemia  leads  to  the  need  for  ABT,
eclined  physical  functioning,  augmented  infection  rates,
onger  hospital  stay,  and  even  mortality.6 In  many  studies,
atient  blood  management  interventions  based  on  postop-
rative  transfusion  of  salvaged  blood  cells  can  provide  a
igniﬁcant  reduction  in  ABTs.6
In  our  study,  the  use  of  the  CS  system  decreased  the
eed  for  ABT  in  the  perioperative  period.  The  mean  ABT
ate  was  92.53  mL  in  the  control  group  and  170.14  mL  in
he  control  group.  The  mean  postoperative  transfusion  rate
n  the  CS  group  was  also  lower  than  that  in  the  control
roup  (125.37  mL  vs.  155.22  mL),  but  the  difference  in  these
esults  did  not  reach  a statistically  signiﬁcant  level.  In  addi-
ion,  the  percentage  of  the  patients  who  received  ABT  was
lso  signiﬁcantly  lower  in  the  CS  group  (n  =  29;  43.2%)  than
n  the  control  group  (n  =  56;  73.6%).  Our  results  are  similar
o  the  results  reported  in  the  literature.  The  results  of  the
tudy  by  Ersen  et  al.7 are  concurrent  with  ours  and  indicated
 perioperative  decrease  in  ABT  rate  when  the  CS  system
as  used  in  posterior  spinal  fusion  surgery.  Their  reported
ean  amount  of  blood  transfused  decreased  from  2.5  U  to
.04  U  when  the  CS  system  was  used.7 In  a  prospective  obser-
ational  cohort  study  on  hip  arthroplasty  revisions  in  which
ell  salvage  group  Control  group  p-value
9  (43.2%)  56  (73.6%)  0.022c
5  (37.3%)  39  (51.3%)  >0.05
2.53  ±  111.88  170.14  ±  116.79  0.001c
5.37  ±  193.33  155.22  ±  208.37  >0.05
3.61  ±  170.99
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Table  3  Hematological  data.
Cell  salvage  group
(mean  ±  SD)
Control  group
(mean  ±  SD)
p-value
Preoperative  hemoglobin  (g/dL)  12.84  ±  1.39  12.50  ±  1.52  >0.05
Discharge hemoglobin  (g/dL)  11.09  ±  1.61  10.95  ±  1.54  >0.05
Preoperative  hematocrit  38.56  ±  3.65  37.43  ±  5.59  >0.05
Discharge hematocrit  33.76  ±  4.92  33.05  ±  4.54  >0.05
Independent samples test.
p > 0.05, no signiﬁcant.
Table  4  Infection  markers.
Cell  salvage  group
(mean  ±  SD)
Control  group
(mean  ±  SD)
p-value
CRPa 10.14  ±  15.82 6.57  ±  9.24 >0.05
Body temperature  (◦C)b 37.59  ±  0.52 37.63  ±  0.47 >0.05
Preoperative  leukocytesb 7620.82  ±  1930.59 7649.53  ±  2686.75 >0.05
Postoperative  leukocytesb 13007.00  ±  4483.51 12158.00  ±  4567.90 >0.05
a Mann--Whitney U test.
b Independent samples test.
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10  cases  were  included,  perioperative  CS  use  decreased  the
hance  of  needing  an  ABT.1 The  results  of  the  study  were
arallel  to  our  ﬁndings.  In  our  logistic  regression  analysis,
erioperative  blood  transfusion  was  identiﬁed  as  signiﬁcant.
n  the  control  group,  the  possibility  of  having  an  ABT  is
lmost  4  times  (OR  =  4.257)  more  likely  than  CS  group.
The  CS  system  has  shown  positive  evidence  for  its  efﬁ-
acy  in  orthopedic  surgery.9 Many  studies  support  the  use
f  the  CS  system  to  reduce  the  necessity  for  ABTs  in  hip
nd  knee  surgeries.10--12 In  a  prospective  study  by  Thomas
t  al.,12 which  included  a  total  of  231  knee  replacement
atients,  a  decrease  in  allogeneic  blood  requirement  was
bserved  in  the  CS  group.12 Despite  the  satisfactory  results
f  knee  and  hip  arthroplasties  owing  to  the  CS  system,
ther  major  orthopedic  surgeries  show  conﬂicting  results.
or  spinal  surgery  or  acetabular  fracture  repair,  some  stud-
es  did  not  report  any  beneﬁt  of  the  CS  system  in  terms
f  reduction  in  the  need  for  ABTs  and  cost.13--16 Scannel
t  al.  retrospectively  evaluated  patients  who  underwent
a
r
s
Table  5  Logistic  regression  analysis  of  risk  factors  effecting  auto
p  
Perioperative  Transfusion  0.001a −
Postoperative  Transfusion  0.094  −
Operation time  (>140  min)  0.007b
Preop Hgb  0.616  
Preop Hct  0.382  
a p< 0.01 statistically signiﬁcant.
b p-value <0.05.pen  reduction  internal  ﬁxation  for  acetabular  fracture  and
ound  no  beneﬁcial  results  for  CS.13 In  the  retrospective
tudy  of  Gause  et  al.,  the  use  of  the  CS  system  in  adult
umbar  spinal  surgery  increased  the  need  for  ABTs.14 Owens
t  al.  also  did  not  report  any  beneﬁcial  results  of  the  CS
ystem  in  adult  lumbar  spinal  surgery  in  their  retrospective
eview. 15
In  contrast,  Ersen  et  al.7 and  Bowen  et  al.17 demonstrated
 decrease  in  ABTs  with  the  CS  system  for  adolescent  sco-
iosis  cases  treated  with  posterior  spinal  fusion.  For  adult
umbar  fusion,  Savvidou  et  al.18 reported  beneﬁcial  results
or  the  CS  system  in  their  prospective  randomized  trial
ncluding  50  patients.  In  their  retrospective  study  on  acetab-
lar  fracture  surgery,  Bigsby  et  al.3 showed  beneﬁcial  results
or  the  CS  system  in  terms  of  cost-effectiveness  and  reducing
he  need  for  ABTs.  In  their  recent  study  designed  for  pedi-
tric  orthopedic  and  cardiac  surgeries,  Samnaliev  et  al.19
eported  the  use  of  the  CS  system  as  cost-effective  and  cost
aving  especially  when  used  along  with  ABT.
logous  blood  transfusion.
ODDS  95%  CI
Lower  Upper
4.257  −0.502  −0.184
1.685  −0.306  0.24
2.720  0.001  0.004
0.502  −0.40  0.068
0.877  −0.010  0.026
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1Cell  salvage  in  hip  arthroplasty  
In  our  study,  operation  time  was  signiﬁcantly  longer  in  the
CS  group.  This  is  because  in  our  institution,  the  CS  system  is
generally  preferred  for  more  complicated  cases  (estimated
blood  loss  >1000  mL,  BMI  >30,  difﬁcult  surgical  technique)
and  the  more  complicated  a  case  becomes,  the  longer  it
takes  to  complete  the  surgery.  Enter  logistic  regression  anal-
ysis,  showed  us,  operation  time  effect  (>140  min)  was  an
independent  risk  factor  for  CS  group.  This  points  outs,  an
almost  2.7  times  more  (OR  =  2.720)  likely  usage  of  CS  system
in  operations  longer  than  140  min.  Although  the  operation
times  were  longer  in  the  CS  group,  less  amount  of  ABT  was
necessary  during  the  surgery,  which  seems  as  a  possible  ben-
eﬁt  for  the  patient.
The  distribution  of  the  male  and  female  populations  was
similar  between  the  groups.  However,  the  proportion  of
female  patients  was  higher  in  both  groups.  This  phenomenon
is  also  speciﬁc  to  our  institution;  that  is,  female  patients
undergo  hip  arthroplasty  surgeries  2  or  3  times  more  fre-
quently  than  male  patients.  An  epidemiological  study  for
a  Turkish  population  who  had  undergone  hip  arthroplasty
surgery  should  be  conducted  to  validate  our  results.
In  terms  of  infection  markers,  we  reviewed  preopera-
tive  CRP  levels,  leukocyte  levels,  and  body  temperatures
for  both  groups.  We  also  reviewed  for  the  highest  postop-
erative  leukocyte  level,  body  temperature,  and  CRP  levels.
We  found  no  statistical  signiﬁcance  in  terms  of  leukocyte
level,  body  temperature,  and  CRP  level  between  the  groups.
A  prospective  observational  study  of  308  patients  found
that  ABT  was  associated  with  an  increased  incidence  of
postoperative  infections  when  compared  with  autologous
transfusion.20
During  the  operation  of  the  patients  in  the  CS  group,  the
mean  amount  of  blood  transfused  from  the  CS  system  was
333  mL.  Our  data  are  similar  to  the  data  obtained  by  Walsh
et  al.,1 who  conducted  a  prospective  cohort  study  for  hip
arthroplasty  revisions  in  11  hospitals  over  a  7-month  period
and  found  a  mean  reinfusion  amount  of  312  mL.21 In  their
retrospective  study,  Jain  and  Jain21 reported  a  slightly  higher
amount  of  salvage  blood  than  that  reported  in  our  present
study,  that  is,  527  mL  for  total  knee  arthroplasty  and  437  mL
for  total  hip  arthroplasty.
The  main  limitation  of  our  study  was  its  design  as  a  ret-
rospective  study.  Another  limitation  was  the  fact  that,  in
our  institution,  our  transfusion  threshold  is  8  g/dL  for  allo-
geneic  blood  transfusion  for  healthy  adults  and  between
8  g/dL  and  10  g/dL  for  patients  with  severe  cardiac  disease,
and  severe  co-morbidities.  But  there  is  an  ongoing  debate
about  transfusion  thresholds  and  conﬂicts  are  unsolved.  As  a
result  different  thresholds  in  different  institutions  can  cause
varied  results.
Blood  transfusion  should  be  avoided  whenever  possible
because  of  the  increased  risk  for  transfusion-transmitted
diseases  and  noninfectious  complications.  All  patient  blood
management  strategies  should  be  considered  during  major
orthopedic  surgery  to  lessen  the  need  for  ABTs.
In  a  Cochrane  Database  Review,  Carless  et  al.5 reported
that  in  cardiac  and  orthopedic  surgeries,  there  is  adequate
proof  of  the  beneﬁts  of  the  CS  system  and  that  it  does  not
cause  any  adverse  events.
Patient  blood  management  is  an  important  issue  for
orthopedic  patients  who  are  candidates  for  arthroplasty
surgeries.  In  our  study,  the  need  for  perioperative  ABT  was
1281
iminished  signiﬁcantly.  Thus,  the  CS  system  may  be  con-
idered  as  an  effective  strategy  for  reducing  the  need  for
BTs;  it  provides  support  to  patient  blood  management.  We
ecommend  the  use  of  the  CS  system  for  hip  arthroplasty
urgeries  if  possible.
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